Month: March 2023

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 22, 2023, to discuss the financial results for the fourth quarter 2022 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13736270. To access the new Call me™ feature, which avoids having to wait for an operator, click here. The live webcast and replay of the conference call can be...

Enlight Renewable Energy Reports Year-End 2022 Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Portfolio Overview Portfolio OverviewAll of the amounts disclosed in this press release are in U.S. dollars unless otherwise noted TEL AVIV, Israel, March 15, 2023 (GLOBE NEWSWIRE) — Enlight Renewable Energy Ltd. (NASDAQ: ENLT, TASE: ENLT) today reported financial results for the full year ended December 31, 2022. The Company’s annually earnings materials and a link to the earnings webcast, which begins today at 8:00 AM ET, may be found on the investor relations section of Enlight’s website at https://enlightenergy.co.il/data/financial-reports/ “We delivered record results in 2022, with revenue up 88% and Adjusted EBITDA* up 96% demonstrating our deep track record of converting projects under development through to construction and operations. We succeeded in bringing over 800 MW to operation, commenced construction on 630 MW...

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2022 financial results and provided an operational update. Recent Financial and Operational HighlightsFor the three months ended December 31, 2022, revenues were $6.0 million, a 29% decrease as compared to the prior year period. As of December 31, 2022, BrainsWay’s Deep TMS™ installed base was 884 total systems, a 17% increase from the installed base at the same point in the prior year. As of December 31, 2022, the Company had shipped 414 obsessive-compulsive disorder (OCD) coils as add-on helmets to certain of BrainsWay’s new and existing systems. Cash, cash equivalents,...

Ebix Reports Record Revenues of $1.1 Billion, 2022 Operating Income of $120.3 Million with 1% YoY Growth, Operating Cash Flow of $32.5 Million in Q4 2022 and $77.6 Million for Fiscal Year 2022, with 12% YOY Growth

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

JOHNS CREEK, Ga., March 15, 2023 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial services, travel, healthcare, and e-learning industries today announced the following results for the quarter ended December 31, 2022 and the full year results for 2022:Revenues of $255.2 million and $1.05 billion for Q4 2022 and fiscal year 2022 2022 GAAP operating income of $120.3 million and Non-GAAP operating income of $137.3 million GAAP Diluted EPS of $2.10 for fiscal year 2022 and Non-GAAP diluted EPS of $2.58 for fiscal year 2022. Operating cash of $32.5 million in Q4 2022 and $77.6 million in fiscal 2022Ebix will host a conference call to review its results today at 11:00 a.m. EDT (details below). Robin Raina, President & CEO,...

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) — Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”) at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on March 28, 2023, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023....

Novotech Publishes Multi-specific Monoclonal Antibodies Global Clinical Trial Landscape Report

Written by Customer Service on March 15, 2023. Posted in Mergers And Acquisitions.

SINGAPORE, March 15, 2023 (GLOBE NEWSWIRE) — Novotech, the leading Asia Pacific centred biotech CRO has published a new report on the current status of clinical trials for multi-specific monoclonal antibodies (Mabs) globally including an analysis of growth hubs across Asia Pacific, Europe, and US. The new report Multi-Specific Monoclonal Antibodies – Global Clinical Trial Landscape can be downloaded here. The report found that between 2018 and 2022 there have been over 1,000 global trials related to multi-specific Mabs, with the Asia Pacific involved in about 40% of the trials, the US about 30%, and Europe about 22%. Asia Pacific has been the fastest-growing region in multi-specific Mabs trials with a 5Y CAGR of over 37% which is nearly twice and three times the growth rates of the US and Europe respectively. The majority of multi-specific...

GDS Holdings Limited Reports Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

SHANGHAI, China, March 15, 2023 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial HighlightsNet revenue increased by 9.9% year-over-year (“Y-o-Y”) to RMB2,404.0 million (US$348.6 million) in the fourth quarter of 2022 (4Q2021: RMB2,187.4 million). Service revenue increased by 10.0% Y-o-Y to RMB2,404.0 million (US$348.6 million) in the fourth quarter of 2022 (4Q2021: RMB2,185.9 million). Net loss was RMB177.9 million (US$25.8 million) in the fourth quarter of 2022 (4Q2021: net loss of RMB312.9 million). Adjusted EBITDA (non-GAAP) increased by 4.3% Y-o-Y to RMB1,071.5...

Kandi Technologies Reports 2022 Financial Results

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Revamped strategy leads to highest revenue in 3 years Optimistic outlook due to strong balance sheet and diversified business modelJINHUA, China, March 15, 2023 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company”, “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the full year ended December 31, 2022. Full Year 2022 HighlightsTotal revenues increased by 28.8% to $117.8 million, from $91.5 million in 2021. Off-road vehicles and associated parts sales increased by 140.7% to $70.6 million, compared to $29.3 million in 2021. EV products sales increased to $7.9 million from $1.5 million in 2021. EV parts sales were $9.0 million, compared to $25.3 million in 2021. Electric Scooters, Electric Self-Balancing Scooters and associated parts sales were $4.6 million, compared with $30.0 million...

Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates. “As we reflect on a productive 2022, Aravive remains committed to driving progress across all aspects of our business,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “We are on track with development activities around our PROC Phase 3 program, and we anticipate delivering topline results in mid-2023. Our trials in both clear cell renal cell carcinoma and pancreatic cancer continue...

HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

Written by Customer Service on March 15, 2023. Posted in Earnings Releases And Operating Results.

Data from Phase 2 study of HB-200 in combination with pembrolizumab in head and neck cancers expected in 2Q 2023Phase 1 HB-300 trial in metastatic castration-resistant prostate cancer open for enrollmentKRAS program (HB-700) achieved its first milestone payment in the Roche collaboration in February 2023; plan to submit IND in 1H 2024Strengthened cash position of $113.4 million at year-end; additional $15.0 million cash inflow from collaboration milestones in early 2023NEW YORK and VIENNA, March 15, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023. “We made...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals